FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org November 5, 2007 (10.1056/NEJMoa0706201)

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients.

Methods A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations.

Results As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group.

Conclusions Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310 [ClinicalTrials.gov] .)

Source Information

Affiliations for authors are listed in the Appendix.

This article (10.1056/NEJMoa0706201) was published at www.nejm.org on November 5, 2007. It will appear in the November 29 issue of the Journal.

Address reprint requests to Dr. Kjekshus at the Department of Cardiology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway, or at john.kjekshus{at}medisin.uio.no.

Full Text of this Article

This article has been cited by other articles:

• Peterson, E. D., Wang, T. Y. (2008). The Great Debate of 2008--How Low to Go in Preventive Cardiology?. JAMA 299: 1718-1720 [Full Text]  
• Torabi, A., Cleland, J. G.F., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., Caplin, J. L., Rigby, A. S., Goode, K. (2008). The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J 29: 859-870 [Abstract] [Full Text]  
• Florkowski, C. M., Molyneux, S. L., George, P. M., Kjekshus, J., McMurray, J. J.V., Wikstrand, J. (2008). Rosuvastatin in Older Patients with Systolic Heart Failure. NEJM 358: 1301-1301 [Full Text]  
• Athyros, V. G., Kakafika, A. I., Tziomalos, K., Karagiannis, A., Mikhailidis, D. P. (2008). CORONA, Statins, and Heart Failure: Who Lost the Crown?. ANGIOLOGY 59: 5-8  
• Ramasubbu, K., Estep, J., White, D. L., Deswal, A., Mann, D. L. (2008). Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.. J Am Coll Cardiol 51: 415-426 [Abstract] [Full Text]  
• Masoudi, F. A. (2007). Statins for Ischemic Systolic Heart Failure. NEJM 357: 2301-2304 [Full Text]  
• (2007). Can Statins Benefit Elderly Patients with Ischemic Heart Failure?. JWatch General 2007: 8-8 [Full Text]